BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 32083444)

  • 1. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update.
    Revaux A; Carbonnel M; Kanso F; Naoura I; Asmar J; Kadhel P; Ayoubi JM
    Horm Mol Biol Clin Investig; 2020 Feb; 41(3):. PubMed ID: 32083444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer.
    Gruner M; Chambers LM; Yao M; Chichura A; Morton M; Costales AB; Horowitz M; Rose PG; Debernardo R; Michener CM
    Gynecol Oncol; 2021 Sep; 162(3):645-651. PubMed ID: 34247768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer.
    Cowan RA; O'Cearbhaill RE; Zivanovic O; Chi DS
    Int J Hyperthermia; 2017 Aug; 33(5):548-553. PubMed ID: 28092994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
    Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience.
    Ghirardi V; Ronsini C; Trozzi R; Di Ilio C; Di Giorgio A; Cianci S; Draisci G; Scambia G; Fagotti A
    Cancer; 2020 Dec; 126(24):5256-5262. PubMed ID: 32931024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
    El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
    ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
    Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
    Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    de Bree E; Michelakis D
    Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. State of the Science: The role of HIPEC in the treatment of ovarian cancer.
    Dellinger TH; Han ES
    Gynecol Oncol; 2021 Feb; 160(2):364-368. PubMed ID: 33419611
    [No Abstract]   [Full Text] [Related]  

  • 13. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Kim SI; Kim JW
    ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Medina-Castro JM; Ruiz-DeLeón A
    Chin Clin Oncol; 2020 Aug; 9(4):44. PubMed ID: 32648446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Bouchard-Fortier G; Cusimano MC; Fazelzad R; Sajewycz K; Lu L; Espin-Garcia O; May T; Bouchard-Fortier A; Ferguson SE
    Gynecol Oncol; 2020 Jul; 158(1):218-228. PubMed ID: 32387131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
    Ansaloni L; Agnoletti V; Amadori A; Catena F; Cavaliere D; Coccolini F; De Iaco P; Di Battista M; Framarini M; Gazzotti F; Ghermandi C; Kopf B; Saponara M; Tauceri F; Vallicelli C; Verdecchia GM; Pinna AD
    Int J Gynecol Cancer; 2012 Jun; 22(5):778-85. PubMed ID: 22572845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyperthermic intraperitoneal chemotherapy for epithelial ovarian cancer: A meta-analysis.
    Kim SI; Kim JH; Lee S; Cho H; van Driel WJ; Sonke GS; Bristow RE; Park SY; Fotopoulou C; Lim MC
    Gynecol Oncol; 2022 Dec; 167(3):547-556. PubMed ID: 36273925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.